Abstract | PURPOSE: METHODS: Thirteen centres in eight European countries participated in this retrospective study. Medical records for patients with any angiographic subtype of subfoveal choroidal neovascularisation secondary to NV-AMD with visual acuities (study eye) of 20/40-20/320 treated with 0.3 mg pegaptanib as first-line treatment and with at least 24 weeks of follow-up were identified. Anonymised data reflecting at least 24 and up to 54 weeks of follow-up were recorded. Primary end points were visual acuity outcomes at weeks 24 and 54 compared with those reported at week 54 in the vascular endothelial growth factor ( VEGF) Inhibition Study in Ocular Neovascularisation (VISION) trial. RESULTS: In all, 253 patients were followed for at least 24 weeks; 62 patients completed 54 weeks of follow-up. A mean of 4.4 (SD, 1.8) pegaptanib injections were administered through 24 weeks. Compared with the VISION trial, the European experience showed that >90% of patients in the current cohort lost <15 letters from baseline at both time points compared with 70% in the VISION trial at 54 weeks. Pegaptanib was well tolerated with no reported cases of endophthalmitis, traumatic cataract, or iatrogenic retinal detachment. CONCLUSIONS:
Pegaptanib was found to stabilise vision in a greater percentage of patients and produced greater overall visual improvement in this group of treatment-naive patients with NV-AMD compared with outcomes reported in the VISION trial; however, interpretation of these results should be tempered given the differences in design between this retrospective study and the prospective controlled trial.
|
Authors | S Sivaprasad, P Hykin, A Saeed, S Beatty, S Grisanti, G Staurenghi, J L Olea, A Campos, A Barbosa, L Rito, R Silva, R Faria, B Eldem, S Kadayifçilar, P Kolar, N Feucht, L Maestroni |
Journal | Eye (London, England)
(Eye (Lond))
Vol. 24
Issue 5
Pg. 793-8
(May 2010)
ISSN: 1476-5454 [Electronic] England |
PMID | 19786957
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Aptamers, Nucleotide
- Vascular Endothelial Growth Factors
- pegaptanib
|
Topics |
- Aptamers, Nucleotide
(therapeutic use)
- Choroidal Neovascularization
(drug therapy, etiology, physiopathology)
- Cohort Studies
- Humans
- Intravitreal Injections
- Macular Degeneration
(complications)
- Retrospective Studies
- Vascular Endothelial Growth Factors
(antagonists & inhibitors)
- Visual Acuity
(physiology)
|